Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Consensus Estimates and Trading Data

In the past 52-week period, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have moved within the range of $31.38 to $126.16. On the stock’s most recent trading day, the company’s shares ended the regular session at $117.07, which is 7.21% lower than its 52-week high.

Alnylam Pharmaceuticals, Inc. (ALNY) has demonstrated a 20-day simple moving average (SMA) of -1.93%, and a 50-day SMA of 18.07%. This public company’s current market capitalization stands at $10.83 billion.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Measuring Wall Street analysts’ average enthusiasm for a specific stock is critical when considering a potential investment. According to the latest data, the consensus recommendation for Alnylam Pharmaceuticals, Inc. (ALNY) is Outperform.

Publicly-traded companies normally report earnings and revenue figures that are either above or below the average Wall Street projection. In the most recent quarterly financial report, for the quarter ending Jun. 2017, Alnylam Pharmaceuticals, Inc. (ALNY) delivered a 28.60% surprise with its net revenue. Sales reached $0.02 billion during the three-month period, compared to the average analyst estimate of $0.02 billion.

Meanwhile, during the same quarter Alnylam Pharmaceuticals, Inc. (ALNY) delivered a -9.67% earnings surprise. Net earnings for the quarter were posted at -$1.34 per share, whereas Wall Street had forecast -$1.22 per share.

Ownership at Alnylam Pharmaceuticals, Inc. (ALNY), According to Most Recent SEC Filings

We can gain important insight by taking a look at institutional ownership, as detailed in public companies’ latest 13F filings. Alnylam Pharmaceuticals, Inc. (ALNY) has 0.09 billion shares outstanding currently, 95.67% of which belong to institutional investors. Those institutional holdings amount to $10.14 billion.

Additionally, according to the most recent 13F filing from Alnylam Pharmaceuticals, Inc. (ALNY), there were 49 new positions totaling 2,329,705 shares of the company’s stock. There were 21 sold out positions, on the other hand, totaling 1,034,031 shares.